What Makes a HealthTech Startup Hard to Scale in Europe?

Why scaling is a distinct challenge for European HealthTech

Europe is a fertile ground for health‑technology ideas. Universities, research hospitals and public‑funded labs generate a steady stream of innovations. Yet many founders find that moving from a prototype or a single‑city pilot to a multi‑country operation is far more difficult than in other tech sectors. The difficulty is not a single obstacle but a combination of regulatory, market, financing and talent factors that intersect in ways that are unique to health‑related products.

Regulatory fragmentation across the EU and beyond

The most visible barrier is the regulatory landscape. In the United States a single federal agency—the Food and Drug Administration (FDA)—sets the rules for most medical devices and diagnostics. In Europe the situation is split between the European Medicines Agency (EMA), the European Union Medical Device Regulation (MDR), the In‑Vitro Diagnostic Regulation (IVDR), and a patchwork of national health authorities.

Multiple approval pathways

• MDR / IVDR compliance. The 2017 MDR replaced the older Medical Device Directive and introduced stricter clinical evidence, post‑market surveillance and documentation requirements. Companies must produce a Technical File that meets the “Essential Requirements” and obtain a CE mark from a designated Notified Body.
• National reimbursement rules. Even with a CE mark, a device may not be reimbursed. Each country maintains its own health‑technology assessment (HTA) body that decides if a product is cost‑effective for the public payer.
• Cross‑border data rules. The General Data Protection Regulation (GDPR) governs patient data handling. While GDPR is uniform across the EU, national implementations (e.g., Germany’s BDSG) add nuance, especially for health‑specific processing activities.

Because the approval process differs from country to country, a startup that hopes to enter five or ten markets must budget for multiple submissions, language translations of technical documentation, and repeated audits.

Reimbursement complexity and price heterogeneity

In the United States, a device that receives FDA clearance can often be priced at the discretion of the manufacturer, with private insurers negotiating rates. In Europe, public insurers dominate, and price setting is a political decision. The same technology may be reimbursed at 100 % of the listed price in Sweden, partially covered in France, and not covered at all in Italy.

Key consequences for scaling include:

• Longer market entry timelines. Negotiations with HTA bodies can take 12–24 months after regulatory approval.
• Variable revenue forecasts. A startup must model each country’s tariff schedule rather than relying on a single price point.
• Need for local health‑economic evidence. Cost‑effectiveness studies must reflect national care pathways, which requires additional clinical data collection.

Fragmented health systems and procurement processes

Europe’s health systems range from the highly centralized NHS in the United Kingdom to the federated, insurance‑driven models of Germany and the Netherlands. Procurement rules differ:

• In the UK, NHS England runs national tenders for certain device categories, requiring suppliers to meet strict framework agreements.
• Germany’s “Konsortialverfahren” allows groups of hospitals to negotiate contracts jointly, but each consortium may have its own criteria.
• France’s “achats publics” process mandates that all public contracts be advertised on a national portal, with specific thresholds for electronic versus paper submission.

For a HealthTech startup, this means building separate sales and legal teams that understand each procurement regime, training them on local tender calendars, and maintaining compliance with differing anti‑corruption and transparency rules.

Funding realities for health‑focused ventures

HealthTech startups often need more capital than a pure software company. Clinical trials, device certification, and regulatory consultancy can exhaust a seed round quickly. While Europe has a growing pool of venture capital (VC) firms that specialize in digital health, the average ticket size remains lower than in North America.

• Stage‑dependent availability. Early‑stage funding (seed to Series A) is typically sourced from angel networks, health‑focused incubators (e.g., EIT Health) or national innovation grants. Larger Series B and C rounds often require a proven regulatory pathway and at least one reimbursement contract.
• Investor risk perception. European VCs tend to be more risk‑averse about lengthy regulatory timelines. They may demand milestones tied to CE marking or HTA approval before committing additional capital.
• Currency and market size considerations. A €10 million raise can fund a pan‑European rollout, but the fragmented market means that the same amount may only support operations in a handful of countries.

Talent acquisition across borders

Successful scaling relies on a multidisciplinary team: regulatory affairs experts, clinical researchers, data scientists, sales professionals fluent in local health‑system language, and software engineers. Europe’s linguistic diversity adds a recruitment hurdle.

• Regulatory expertise is scarce. Professionals who have navigated MDR, IVDR and national HTA processes are limited in number, and they often command premium salaries.
• Clinical trial staff vary by country. Investigators, site coordinators and ethics‑committee administrators each operate under national rules, making cross‑border trial management complex.
• Language requirements for sales. Healthcare providers expect communication in their native language, and procurement documentation must be localized.

Data interoperability and standards

HealthTech solutions that rely on electronic health records (EHR) or patient‑generated data must communicate with existing hospital information systems. Europe does not have a single dominant EHR platform; instead, each country (and often each hospital) uses a different vendor and data model.

• Standards adoption is uneven. While HL7 FHIR is promoted by the EU, actual implementation varies, and many legacy systems still rely on older HL7 v2 messages or proprietary APIs.
• Cross‑border data exchange is limited. GDPR permits health data processing for research, but moving data between countries for commercial purposes often requires additional Data Processing Agreements (DPAs) and ethical approvals.
• Impact on product architecture. Developers must build flexible integration layers that can map to multiple standards, increasing development time and testing effort.

Intellectual property (IP) strategy in a multi‑jurisdiction environment

Patents filed through the European Patent Office (EPO) grant protection across designated member states, but the process is lengthy (average 3‑5 years) and costly. Some startups opt for national filings to reduce upfront expense, but that fragments protection and complicates enforcement.

Key considerations for scaling:

• Timing of filings. Early public disclosure (e.g., conference presentations) can jeopardize patentability in countries that require absolute novelty.
• Cost of maintenance. Annual renewal fees differ by country; maintaining a pan‑European portfolio can become a significant line‑item.
• Strategic licensing. In markets where a startup cannot secure direct reimbursement, licensing the technology to a local partner may be more viable.

Cultural expectations and patient adoption

Beyond legal and financial constraints, patient behaviour influences scalability. Trust in digital health varies widely:

• Scandinavian countries exhibit high acceptance of remote monitoring and telemedicine, partly due to early government pilots.
• Southern European markets often prefer in‑person consultations, making adoption of AI‑driven diagnostics slower.
• Language and health literacy affect how patients engage with mobile apps, requiring localized UX design and targeted education campaigns.

Launching the same app in France and Poland without adapting the onboarding flow may lead to high drop‑off rates in one market while performing well in the other.

Infrastructure disparities

Reliable broadband, hospital IT infrastructure and digital health ecosystems differ between regions. Rural areas in Eastern Europe may struggle with 4G coverage, limiting the feasibility of real‑time remote monitoring solutions. Conversely, well‑connected urban centres in the Netherlands can support high‑bandwidth AI analytics.

Startups must assess the technical prerequisites of each target market and possibly design tiered product versions—offline‑capable modules for low‑bandwidth environments and full‑cloud features for high‑capacity settings.

Legal and contractual hurdles

Contracts with hospitals, insurers and public purchasers are governed by national law. Differences include:

• Liability clauses that allocate risk differently under German “Produkthaftung” versus the UK’s “Consumer Rights Act.”
• Mandatory local representation requirements in countries such as France, where a “mandataire” must be appointed for legal service of process.
• Public‑procurement statutes that dictate lead‑time, bidding documentation, and anti‑collusion measures.

Failure to tailor agreements to local legal frameworks can delay contract signing or expose the company to unexpected litigation.

Roadmap for overcoming scaling barriers

While the challenges are numerous, they are not insurmountable. Successful European HealthTech startups typically follow a phased, evidence‑driven approach:

1. Choose a launch country with a favourable regulatory‑reimbursement mix. Many founders start in a nation where the MDR pathway is well‑documented and the HTA body offers fast‑track assessment (e.g., the Netherlands or the UK).
2. Secure a “regulatory anchor.” Obtain CE marking early and use it as a credential for other markets. The CE mark is recognized across the EU, even if additional national filings are needed later.
3. Build a modular product architecture. Separate the core algorithm from integration adapters, allowing quick re‑configuration for each country’s data standards.
4. Develop a country‑specific reimbursement plan. Map out the HTA pathway, identify required health‑economic studies, and engage local Key Opinion Leaders (KOLs) to champion the value proposition.
5. Leverage EU‑wide funding mechanisms. Programs such as Horizon Europe, the European Innovation Council, and national “Smart Specialisation” funds can de‑risk early clinical validation.
6. Establish a local presence. Even a small office or a dedicated “country manager” helps navigate procurement, language, and cultural nuances.
7. Create a scalable regulatory affairs function. Centralize core documentation while delegating country‑specific submissions to local experts.
8. Plan for post‑market surveillance. MDR requires ongoing safety monitoring; setting up a Europe‑wide vigilance system early avoids costly retrofits.

Illustrative example: A remote cardiac monitoring startup

Consider a company that has developed a wearable ECG device with AI‑based arrhythmia detection. Its first market is Denmark, chosen for high digital health adoption and a streamlined reimbursement pathway through the Danish Health Technology Assessment (HTA) agency.

Steps taken:

• Obtained CE marking under MDR Class IIb with a Notified Body experienced in cardiovascular devices.
• Ran a pilot in three Danish hospitals, collecting real‑world data to support a cost‑effectiveness model.
• Negotiated a tariff with the Danish Regions that covered the device and associated data‑service subscription.
• Used the Danish success story and CE mark to submit a parallel HTA dossier in Germany, tailoring the economic model to German DRG reimbursement.
• Partnered with a German medical‑device distributor who already had a local “mandataire” in place, reducing legal friction.
• Adapted the device’s firmware to support both FHIR and the legacy HL7 v2 messages used by German hospital systems.
• Secured a €5 million Series B round led by a European health‑tech fund, citing the dual‑country traction as evidence of scalability.

Within 18 months, the startup expanded to four additional EU countries, each time re‑using the core regulatory package and adapting only the reimbursement and integration layers. The example shows that a disciplined, incremental approach can convert a fragmented landscape into a series of manageable steps.

Key take‑aways for founders

• Regulatory fragmentation is the primary scaling bottleneck; treat the CE mark as a minimum viable product for Europe, not the final destination.
• Reimbursement is country‑specific; early engagement with HTA bodies and local KOLs shortens market‑entry timelines.
• Build a flexible technical stack that can plug into multiple data standards and operate offline when needed.
• Allocate budget for local talent, legal counsel, and translation—these costs are not optional.
• Leverage EU‑level funding and incubator programmes to offset the high upfront cost of clinical validation.